FDA fast-tracks psychedelic drug research following Trump executive order

Scroll

It's a big shift toward supporting psychedelic-based medicines for treatment-resistant depression, PTSD and substance use disorders, the FDA said.

Coverage and analysis from United States of America. All insights are generated by our AI narrative analysis engine.

United States of America

Bias: lean left

0/500

Note: Comments are moderated. Please keep it civil. Max 3 comments per day.

No recent articles found in this language.